SCYNEXIS, Inc. (SCYX) — Analysis Summary
SCYNEXIS, Inc. (SCYX) has a market cap of $40.10M with year-over-year revenue growth of +449.9%. Net margin stands at -41.8%. The stock trades at a P/E ratio of -3.9.
Key Takeaways
- Revenue changed +449.9% year-over-year
- Net margin of -41.8%
- P/E ratio of -3.9
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, SCYX posted revenue growth of +449.9% and trades at a P/E of -3.9.
SCYNEXIS, Inc. (SCYX)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -117.6% — severe operating losses
Net margin at -53.3% — significant losses
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
29
Headquarters
JERSEY CITY, NJ
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.